New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The pipeline has failed, sales of migraine drug Vypeti, which cost billions to acquire, have failed, and so, it seems, has the firm’s ability to make money. Still, the pharmaceutical company’s new CCO, Jacob Tolstrup, is optimistic on Lundbeck’s behalf.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's migraine drug approved in EU
For subscribers
